Crescent Biopharma, Inc.
CBIONASDAQHealthcare● Active
$18.15
+$0.87(+5.01%)
Market Cap$500319697
P/E Ratio—
52W High$27.41
52W Low$8.72
Crescent Biopharma, Inc. (CBIO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CBIO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $10.84M | $0.00M | $0.01M | $0.07M | $1.16M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $10.84M | $0.00M | $0.01M | $0.07M | $1.16M |
| Gross Margin %(computed) | 100.00% | — | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $138.09M | $28.06M | $20.07M | $28.39M | $47.49M |
| G&A Expenses | $25.39M | $16.32M | $19.21M | $19.09M | $17.12M |
| Total Operating Expenses | $163.48M | $49.90M | $39.29M | $47.48M | $64.61M |
| Operating Income | ($152.63M) | ($49.90M) | ($39.28M) | ($47.40M) | ($63.45M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $2.88M | $1.00M | $2.38M | $0.71M | $0.02M |
| Interest Expense | $2.19M | $0.85M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($151.94M) | ($48.52M) | ($36.90M) | ($46.69M) | ($63.43M) |
| Income Tax Expense | $2.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($153.94M) | ($48.52M) | ($36.90M) | ($46.69M) | ($63.43M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-14.78 | $-1.40 | $-0.58 | $-0.89 | $-1.23 |
| Wtd Avg Shares | 10.41M | 19.50M | 63.34M | 52.53M | 51.45M |
| EBITDA | ($149.67M) | ($44.17M) | ($39.12M) | ($47.20M) | ($63.18M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Crescent Biopharma, Inc. data
About Crescent Biopharma, Inc. (CBIO) Income Statement
Crescent Biopharma, Inc. (CBIO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CBIO reported revenue of $0.01B, gross profit of $0.01B (gross margin 100.00%), and net income of ($0.15B) — a net profit margin of -1419.61%.
Frequently asked questions
CBIO · 4 questionsCrescent Biopharma, Inc. (CBIO) reported revenue of $0.01B for 2025, up —% year-over-year.
CBIO revenueCBIO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09